Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2025-06-13 00:00:00 ET · period of report 2025-06-11 · accession 0001415889-25-017311 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-13 | 2025-06-11 | JANX | Simson Jake | Dir | A - Grant | $0.00 | +3,750 | 6,250 | +150% | $0 |
| D | 2025-06-13 | 2025-06-11 | JANX | Simson Jake | Dir | A - Grant | $0.00 | +11.7K | 11.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-11 | A | A | 3,750 | $0.00 | 6,250 | D | — | — | (F1) Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. (F2) Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Advisor"), the Reporting Person holds the option and RSUs reported on this Form 4 for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock. |
| 2 | Derivative | Stock Option (right to buy) | 2025-06-11 | A | A | 11,667 | $0.00 | 11,667 | D | $25.46 · — to 2035-06-10 | 11,667 Common Stock | (F2) Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Advisor"), the Reporting Person holds the option and RSUs reported on this Form 4 for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock. (F3) The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. |